Cash and cash equivalents were EUR236M as of March 31, compared to EUR281M for December 31, 2024.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
- Pharvaris initiated with an Overweight at Cantor Fitzgerald
- Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
- Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
- Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating